Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,028,464
  • Shares Outstanding, K 36,068
  • Annual Sales, $ 150 K
  • Annual Income, $ -152,990 K
  • 60-Month Beta 1.26
  • Price/Sales 13,182.74
  • Price/Cash Flow N/A
  • Price/Book 5.03
Trade KROS with:

Options Overview Details

View History
  • Implied Volatility 71.83% ( +1.15%)
  • Historical Volatility 45.19%
  • IV Percentile 71%
  • IV Rank 30.07%
  • IV High 120.84% on 11/16/23
  • IV Low 50.76% on 12/15/23
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 732
  • Open Int (30-Day) 1,180

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.31
  • Number of Estimates 8
  • High Estimate -1.20
  • Low Estimate -1.62
  • Prior Year -1.26
  • Growth Rate Est. (year over year) -3.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.24 +1.78%
on 04/25/24
67.49 -19.71%
on 03/26/24
-12.07 (-18.22%)
since 03/25/24
3-Month
50.10 +8.16%
on 02/08/24
73.00 -25.77%
on 02/29/24
-2.10 (-3.73%)
since 01/25/24
52-Week
27.02 +100.56%
on 10/26/23
73.00 -25.77%
on 02/29/24
+10.33 (+23.55%)
since 04/25/23

Most Recent Stories

More News
Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KROS : 54.19 (-3.65%)
Why Shares of Keros Therapeutics Jumped This Week

The company appointed a new director and an analyst reiterated his position on the stock.

BIIB : 202.46 (+0.23%)
VIR : 7.63 (-5.10%)
KROS : 54.19 (-3.65%)
Is a Surprise Coming for Keros Therapeutics (KROS) This Earnings Season?

Keros Therapeutics (KROS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

KROS : 54.19 (-3.65%)
Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KROS : 54.19 (-3.65%)
Wall Street Analysts Think Keros Therapeutics, Inc. (KROS) Could Surge 95%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 94.9% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questionable,...

KROS : 54.19 (-3.65%)
Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KROS : 54.19 (-3.65%)
Wall Street Analysts Believe Keros Therapeutics, Inc. (KROS) Could Rally 96%: Here's is How to Trade

The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 96.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

KROS : 54.19 (-3.65%)
Why Shares of Keros Therapeutics Rose 10.2% This Week

A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.

MRK : 130.72 (+2.93%)
KROS : 54.19 (-3.65%)
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring...

KROS : 54.19 (-3.65%)
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

KROS : 54.19 (-3.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 56.89
2nd Resistance Point 55.97
1st Resistance Point 55.08
Last Price 54.19
1st Support Level 53.27
2nd Support Level 52.35
3rd Support Level 51.46

See More

52-Week High 73.00
Fibonacci 61.8% 55.44
Last Price 54.19
Fibonacci 50% 50.01
Fibonacci 38.2% 44.58
52-Week Low 27.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar